Advertisement

Protein & Cell

, Volume 9, Issue 2, pp 196–206 | Cite as

Structural and functional roles of ether lipids

  • John M. Dean
  • Irfan J. Lodhi
Open Access
Review

ABSTRACT

Ether lipids, such as plasmalogens, are peroxisome-derived glycerophospholipids in which the hydrocarbon chain at the sn-1 position of the glycerol backbone is attached by an ether bond, as opposed to an ester bond in the more common diacyl phospholipids. This seemingly simple biochemical change has profound structural and functional implications. Notably, the tendency of ether lipids to form non-lamellar inverted hexagonal structures in model membranes suggests that they have a role in facilitating membrane fusion processes. Ether lipids are also important for the organization and stability of lipid raft microdomains, cholesterol-rich membrane regions involved in cellular signaling. In addition to their structural roles, a subset of ether lipids are thought to function as endogenous antioxidants, and emerging studies suggest that they are involved in cell differentiation and signaling pathways. Here, we review the biology of ether lipids and their potential significance in human disorders, including neurological diseases, cancer, and metabolic disorders.

Keywords

ether lipids plasmalogen phospholipid peroxisomes cancer metabolic disorders 

INTRODUCTION

Conventional glycerophospholipids have acyl chains attached to the sn-1 and sn-2 positions of the glycerol backbone by ester bonds. Ether lipids are a unique class of glycerophospholipids that have an alkyl chain attached to the sn-1 position by an ether bond (Fig. 1). The alcohol moiety attached to the phosphate group in ether lipids is generally choline or ethanolamine, but occasionally inositol or serine have also been observed. Ether lipids constitute approximately 20% of the total phospholipid pool in mammals, but tissue distribution varies. The highest levels are found in the brain, heart, spleen, and white blood cells, while liver has scant amount of intracellular ether lipids (Braverman and Moser, 2012).
Figure 1

Chemical structures of diacyl and ether-linked phospholipids. Diacyl phospholipids have fatty acyl side chains linked to the sn-1 and sn-2 position of the glycerol backbone by ester bonds. Ether-linked phospholipids are a subclass of glycerophospholipids that have an alkyl chain attached by an ether bond at the sn-1 position. The sn-2 position of ether lipids generally has an ester-linked acyl chain, as in diacyl phospholipids. Some ether-linked phospholipids, called alkenyl-acylphospholipids, contain a cis double bond adjacent to the ether linkage and are commonly referred to as plasmalogens. The polar head group of ether-linked phospholipids is most commonly choline or ethanolamine

Plasmalogens are the most common form of ether lipids and are characterized by a cis double bond adjacent to the ether linkage. Plasmalogens were serendipitously discovered in 1924 by Feulgen and Voit while staining tissue sections with a nuclear stain that reacts with aldehydes released by acid hydrolysis of DNA (Snyder, 1999). Because the acid treatment also resulted in breakdown of the vinyl ether bond of plasmalogens to generate aldehydes, the researchers unexpectedly also observed cytoplasmic staining and named the unknown source of aldehydes “plasmalogens”. The study of plasmalogens and ether lipids in general has been long and arduous and in the beginning the progress was slow and scattered. Recently, much advancement has been made in our understanding of the roles of ether lipids in health and disease.

In this review, we outline the pathway of ether lipid biosynthesis and then describe the unique structural roles played by ether lipids in mammalian cell membranes, followed by a discussion of emerging cellular functions of these lipids. Lastly, we review the current knowledge of the role of ether lipid metabolism in disease.

BIOSYNTHESIS OF ETHER LIPIDS

Ether lipids are synthesized through a well-characterized process that begins in the peroxisome and is completed in the ER (Fig. 2). The peroxisomal component is referred to as the acyl-dihydroxyacetone (DHAP) pathway since DHAP, a glycolysis intermediate, is used as a precursor for ether lipid synthesis (Hajra and Das, 1996). Fatty acids for ether lipid synthesis are thought to be derived from fatty acid synthase (FAS)-mediated de novo lipogenesis or dietary sources (Lodhi et al., 2012, 2015). FAS, a large multifunctional enzyme that primarily synthesizes palmitate (C16:0), is partially localized to the peroxisomes, where it interacts with various peroxisomal proteins (Hillebrand et al., 2012; Lodhi et al., 2012; Cader et al., 2016). In order to be used for ether lipid synthesis, fatty acids are first activated to fatty acyl-CoAs by an acyl-CoA synthetase (ACS) associated with the peroxisomal membrane. Glyceronephosphate O-acyltransferase (GNPAT), a peroxisomal matrix protein, uses a long chain acyl-CoA to acylate DHAP at the sn-1 position. The next peroxisomal step is catalyzed by alkylglycerone phosphate synthase (AGPS) and results in the formation of the ether bond at the sn-1 position by exchanging an acyl chain for an alkyl group. The alkyl moiety used in the AGPS-catalyzed step is generated by a peroxisomal membrane-associated fatty acyl-CoA reductase (FAR1 or FAR2), which reduces an acyl-CoA to a fatty alcohol. The final peroxisomal step in ether lipid synthesis is carried out by acyl/alkyl-DHAP reductase, which reduces alkyl-DHAP into the ether lipid precursor 1-O-alkyl glycerol-3-phosphate (AGP). The DHAP reductase can also reduce acyl-DHAP to generate the diacyl phospholipid precursor lysophosphatidic acid (LPA) as an alternative to direct acylation of glycerol-3-phosphate (G3P) by a G3P acyltransferase (GPAT) (Hajra and Das, 1996). Further steps to convert AGP or LPA to corresponding ether-linked or diacyl glycerolipids, such as phosphatidylcholine or phosphatidylethanolamine, take place in the ER (Hajra and Das, 1996; Gibellini and Smith, 2010). Tethering of peroxisomes to the ER for completion of lipid synthesis was recently shown to involve interaction of the peroxisomal protein acyl-CoA-binding domain 5 (ACBD5) with VAMP-associated proteins A and B (VAPA and VAPB), ER-resident proteins that recruit organelles to the ER (Hua et al., 2017). The precise mechanism through which the ACBD5-VAP complex permits exchange of lipids between the organelles is unclear.
Figure 2

Acyl-DHAP pathway of ether lipid synthesis. This process begins in peroxisomes and is subsequently completed in the ER. The pathway utilizes dihydroxyacetone phosphate (DHAP) generated by glycerol 3-phosphate dehydrogenase (G3PDH)-mediated dehydrogenation of G3P as the substrate for ether lipid synthesis. Fatty acid synthase (FAS)-mediated de novo lipogenesis generates fatty acyl-CoA that is utilized by glyceronephosphate O-acyltransferase (GNPAT) or reduced to a fatty alcohol by a fatty acyl-CoA reductase (FAR1 or FAR2) to later be catalyzed by alkylglycerone phosphate synthase (AGPS), forming the ether bond and exchanging the acyl chain for an alkyl group. PexRAP (an acyl/alkyl DHAP reductase) then catalyzes the final peroxisomal step, generating the ether lipid precursors, 1-O-alkyl-G3P (AGP) or the diacyl phospholipid precursor lysophosphatidic acid (LPA). The completion of phospholipid synthesis occurs in the ER. This includes acylation of the glycerol backbone at the sn-2 position, converting LPA to diacylglycerol (DAG) and AGP to alkyl-acylglycerol (AAG), as well as addition of a cytidine diphosphate-alcohol head group (such as CDP-choline or CDP-ethanolamine) at the sn-3 position to form the mature phospholipid

Although the acyl/alkyl-DHAP reductase protein was purified from guinea pig liver and biochemically characterized over 40 years ago (LaBelle and Hajra, 1974), the gene encoding this enzyme in mammals remained unknown. We recently identified this gene as dhrs7b and renamed the protein PexRAP (for peroxisomal reductase activating PPARγ) based on its proposed function in adipose tissue (Lodhi et al., 2012). Unlike inactivation of GNPAT (also called DHAP acyltransferase), which results in almost complete loss of ether lipids (Rodemer et al., 2003), knockout of PexRAP in mice results in 50–80% decrease in the ether lipid levels (Lodhi et al., 2015). Similarly, approximately 50% decrease in ether lipids was observed in a mutant of CHO-K1 cells with almost complete absence of acyl/alkyl DHAP reductase activity isolated in an ethyl methanesulfonate (EMS) mutagenesis screen (James et al., 1997), suggesting that there is a salvage pathway of ether lipid synthesis. The precise nature of this salvage pathway is poorly understood, but is thought to involve dephosphorylation of alkyl-DHAP to alkyl-dihydroxyacetone, followed by its reduction to alkyl-glycerol, which upon phosphorylation can re-enter the biosynthetic pathway downstream of acyl/alkyl-DHAP reductase (James et al., 1997).

BIOLOGICAL FUNCTIONS OF ETHER LIPIDS

Ether lipids are chemically distinct from their diacyl counterparts, allowing them to contribute unique structural characteristics to biological membranes, which affect such factors as membrane fluidity and membrane fusion. In addition to these effects on membrane dynamics, studies with in vitro and in vivo models of ether lipid deficiency suggest that ether lipids are involved in a variety of biological functions, including regulating cell differentiation, impacting cellular signaling, and reducing oxidative stress through their ability to function as potential endogenous antioxidants.

Structural roles

Ether lipids are a major structural component of cell membranes. The incorporation of ether-linked alkyl chains in phospholipids alters their physical properties and affects membrane dynamics. This is largely attributed to the lack of a carbonyl oxygen at the sn-1 position, which facilitates stronger intermolecular hydrogen bonding between the headgroups (Lohner, 1996). Moreover, the vinyl-ether linkage of plasmalogens at the sn-1 position allows the proximal regions of the sn-1 and sn-2 chains to become parallel, favoring close alignment (Han and Gross, 1990; Paltauf, 1994), therefore permitting tighter packing of phospholipids in the membrane resulting in decreased membrane fluidity and increased rigidity. This property is particularly important in higher order membrane structures such as those found in myelin, evidenced by its enrichment in plasmalogens (Farooqui and Horrocks, 2001). Both ether lipid-deficient mouse models and human patients with ether lipid deficiency often display defects in myelination in both the central and peripheral nervous systems (da Silva et al., 2012).

Plasmalogens are enriched in lipid raft microdomains (LRM), cholesterol-rich regions of membranes where many cellular signaling proteins are concentrated (Pike et al., 2002; Rodemer et al., 2003). Recently, lipidomic analysis of rat synaptic membranes during the first 60 days of postnatal development showed dynamic changes in membrane lipids, including the progressive accumulation of plasmalogens along with cholesterol and sphingolipids. Reconstitution of this membrane remodeling in a model membrane system was associated with enhancement of raft domain stability (Tulodziecka et al., 2016). Consistent with the requirement of plasmalogens in the organization of LRM, plasmalogen-deficient GNPAT knockout mice display disrupted lipid raft formation and mislocalization of cholesterol to a perinuclear compartment (Rodemer et al., 2003).

Disruption of cellular phospholipid composition affects membrane integrity (Li et al., 2006), activates ER stress (Fu et al., 2011; Volmer et al., 2013), and promotes apoptosis (Yen et al., 1999). It has long been known that ether-linked phospholipids are abundantly present in neutrophils, constituting nearly half of the phosphatidylcholine pool (Mueller et al., 1982, 1984; Bräutigam et al., 1996; Nagan and Zoeller, 2001). However, the physiological significance of these lipids in neutrophils has remained unclear. Our recent studies with genetic inactivation of lipogenesis in mice suggest that ether lipids are an important membrane component required for survival of mature neutrophils (Fig. 3). Tamoxifen-inducible global knockout of FAS results in a preferential decrease in ether-linked glycerophosphocholines (ether-lipid equivalent of phosphatidylcholine; GPC) in neutrophils (Lodhi et al., 2015), increased ER stress and apoptosis, resulting in nearly complete neutropenia, suggesting that FAS channels fatty acids to peroxisomes for lipid synthesis. Indeed, FAS has been shown to interact with PMP70, an ATP binding cassette subfamily D transporter that transports fatty acyl CoA into peroxisomes (Hillebrand et al., 2012), directly linking FAS to peroxisomal lipid metabolism. Consistent with the importance of peroxisome-derived lipids in neutrophil survival, tamoxifen-inducible knockout of PexRAP also results in neutropenia due to decreased ether lipid levels, recapitulating the results obtained with FAS knockout (Lodhi et al., 2015). These results suggest that peroxisome-derived lipids, including ether lipids, are an important structural component of neutrophil membranes and reveal a novel lipogenic pathway that selectively regulates neutrophil development.
Figure 3

Peroxisomal lipid synthesis is required for maintaining neutrophil viability and membrane integrity. In healthy neutrophils, fatty acid synthase (FAS) and PexRAP participate in peroxisomal lipid synthesis, including the generation of ether-linked phospholipids that are incorporated into the plasma membrane, contributing to membrane integrity. Genetic ablation of FAS or PexRAP disrupts the lipid synthetic pathway, leading to a preferential loss of ether-linked phospholipids in neutrophils. This alters membrane stability, leading to the activation of ER stress, increased apoptosis, and ultimately neutropenia

Membrane trafficking

Model membranes enriched in plasmalogens have a greater tendency to form non-lamellar inverse hexagonal structures at lower temperatures as compared to such membranes composed of diacyl phospholipids (Glaser and Gross, 1994). Since a transition from a lamellar (no curvature) to an inverted hexagonal (negative curvature) phase is required for membrane fusion (Marrink and Mark, 2004), this property of plasmalogens has been linked to their role in facilitating processes of membrane trafficking. Notably, synaptic vesicles are enriched in ether lipids, and neurotransmitter release from these vesicles into the presynaptic cleft is impaired in the synaptosomes (nerve terminals) isolated from the brains of ether lipid deficient mice (Brodde et al., 2012). In further support of the notion that ether lipids facilitate membrane fusion processes, ether lipid deficiency disrupts the integrity of the blood-testis barrier by affecting the sorting, endocytosis, and recycling of tight junction proteins (Komljenovic et al., 2009). Moreover, plasmalogens have been implicated in cholesterol transport. CHO cells with a defect in plasmalogen synthesis have impaired plasma membrane to ER transport and esterification of cholesterol (Munn, 2003). It is unclear whether plasmalogens directly regulate cholesterol transport through effects on membrane dynamics or if a signaling molecule released from hydrolysis of plasmalogens is involved in the process.

Cell signaling and differentiation

In addition to their structural roles, ether lipids can also act as biological signaling molecules. Oxidation of the vinyl-ether bond of plasmalogens by brominating species produced by an eosinophil peroxidase in activated eosinophils results in a α-bromo fatty aldehyde that acts as a phagocyte chemoattractant for the recruitment of other leukocytes to sites of inflammation (Thukkani et al., 2002; Albert et al., 2003). Moreover, ether-linked mono-alkyl glycerophosphates serve as endogenous antigens to activate invariant natural killer T (iNKT) cells. GNPAT-deficient mice show impaired thymic maturation of iNKT cells and have a reduced overall number of iNKT cells in the thymus and periphery, suggesting that ether lipids are important for the development of these cells (Facciotti et al., 2012).

Ether lipids have also been identified as potential endogenous ligands of peroxisome proliferator-activated receptor gamma (PPARγ) (Davies et al., 2001; McIntyre et al., 2003; Zhang et al., 2004; Tsukahara et al., 2006), a nuclear receptor critical for adipose tissue development and lipid metabolism, which is the target of the glitazone family of diabetes drugs. Using an unbiased mass spectrometry-based approach, we identified several ether-linked GPC species that were bound to PPARγ in a rosiglitazone-displaceable manner. Treatment of cells with one of these lipid species promoted PPARγ-dependent luciferase reporter activity (Lodhi et al., 2012). Furthermore, inhibition of ether lipid biosynthesis by knockdown of PexRAP blocks PPARγ dependent gene expression and adipocyte differentiation. This effect was rescued by rosiglitazone treatment, suggesting that peroxisomal lipid synthesis is involved in endogenous ligand generation (Lodhi et al., 2012). Recently, disruption of peroxisomal biogenesis by Pex16 knockdown was shown to impair PPARγ activation and adipocyte differentiation. The defect in adipogenesis was rescued with the treatment of alkyl glycerol (Hofer et al., 2017), an ether lipid precursor that enters the synthetic pathway downstream of the peroxisomal steps.

Ether lipids have also been implicated in the differentiation of other cell types. In the peripheral nervous system, Schwann cells are required for maintaining axonal health and myelination. Impaired ether lipid synthesis is associated with defects in myelination and myelin structure (Brites, 2003; Rodemer et al., 2003; Teigler et al., 2009). Recent studies suggest that this may be related to the requirement of plasmalogens in Schwann cell differentiation and function. Plasmalogen deficiency mediated by GNPAT or Pex7 knockout in mice impairs membrane recruitment and activation of Akt, resulting in hyperactivation of glycogen synthase kinase 3β (GSK3β), which inhibits Schwann cell differentiation (Fig. 4). This in turn impairs axonal sorting and myelination. Inhibition of GSK3β using lithium rescues Schwann cell differentiation, bypassing the effect of plasmalogen deficiency (da Silva et al., 2014). Plasmalogens have also been implicated in Akt signaling in other cell types. Plasmalogens protect against apoptosis induced through serum starvation by modulating Akt signaling, a pathway possibly mediated through plasmalogens’ ability to activate G-protein coupled receptor signaling (Hossain et al., 2013, 2016). Supplementation of Neuro-2 cells with plasmalogens suppress neuronal apoptosis signaling induced via serum starvation (Yamashita et al., 2015a).
Figure 4

Role of ether lipids in Schwann cell differentiation and myelination. In a healthy Schwann cell, the cell membrane is enriched in plasmalogens. This is necessary for proper recruitment of Akt to the plasma membrane, resulting in its phosphorylation and activation. Activated Akt phosphorylates GSK3β at Ser9, inhibiting its activity. Plasmalogen deficiency impairs recruitment and activation of Akt, preventing it ability to inhibit GSK3β. Active GSK3β impairs Schwann cell differentiation, resulting in disrupted radial sorting and myelination. Supplementation of lithium or TDZD-8 to inhibit GSK3β rescues plasmalogen-deficient phenotype, restoring differentiation and myelination

Plasmalogens as cellular antioxidants

Plasmalogen-deficient cultured cells and animals have long been known to be more sensitive to oxidative damage as compared to their wild-type counterparts, setting the basis for the notion that plasmalogens may function as cellular antioxidants (Morand et al., 1988; Zoeller et al., 1988; Reiss et al., 1997). This is thought to be due to the presence of the vinyl ether bond, which makes plasmalogens susceptible to oxidative attacks. In particular, there is evidence to suggest that plasmalogens could protect unsaturated membrane lipids from oxidation by singlet oxygen (Broniec et al., 2011). Plasmalogens may also be involved in scavenging a variety of reactive oxygen species (ROS) (Morand et al., 1988; Khaselev and Murphy, 1999; Maeba et al., 2002; Skaff et al., 2008). Recent studies suggest that myelin in sciatic and optic nerves from plasmalogen-deficient mice lacking the peroxisomal biogenesis factor Pex7 is significantly more susceptible to oxidative damage than the myelin from wild-type mice (Luoma et al., 2015).

The idea that plasmalogens have a protective role against oxidative damage is difficult to validate directly in complex biological systems. Paradoxically, pro-oxidant effects of these lipids have also been reported in a bulk lipid system (Wang and Wang, 2010). A recent study using synthetic choline plasmalogens in model membrane systems suggests that the antioxidant effect of plasmalogens occurs intramolecularly rather than intermolecularly and depends on the degree of unsaturation of the sn-1 and sn-2 chains, the length of these chains, and their conformation in membranes (Broniec et al., 2017). This suggests that the antioxidant capacity of plasmalogens may be contextually dependent.

ETHER LIPIDS IN DISEASE

The critical importance of ether lipids for health in humans is highlighted by the severity of inherited peroxisomal disorders caused by ether lipid deficiency. Emerging studies suggest that altered ether lipid production is also associated with several other disorders including neurodegenerative diseases, cancer, and metabolic disorders. However, the molecular mechanisms underlying the role of ether lipids in these diseases remain unclear for the most part, suggesting a need for future research.

Genetic peroxisomal disorders resulting in ether lipid deficiency

Rhizomelic chondrodysplasia punctata

Rhizomelic chondrodysplasia punctata (RCDP) is a peroxisomal disorder caused by ether lipid deficiency. RCDP is a multisystem, developmental disorder and has a rare occurrence affecting approximately 1/100,000 individuals. Symptoms include not only those that give the disease its namesake, shortening of limbs (rhizomelia) and multiple punctate epiphyseal calcification (chondrodysplasia punctata), but also microcephaly, distinct facial features, cataracts, and psychomotor retardation. The disease is fatal with patients rarely surviving past the tenth year of life (Braverman and Moser, 2012; White et al., 2003). The most common form is RCDP type 1, which is caused by mutations in Pex7, a peroxisomal import receptor for proteins, including AGPS, that contain a type 2 peroxisomal targeting sequence (PTS), resulting in defects in peroxisomal biogenesis (Braverman et al., 1997; Motley et al., 1997; Purdue, 1997). The less common RCDP types 2 and 3 are caused by single enzyme mutations in either the GNPAT or AGPS genes, respectively, and result in deficient ether lipid biosynthesis. Recently, two new types of RCDP have been reported. RCDP type 4 results from a mutation in FAR1, which is required for the conversion of fatty acyl-CoAs to fatty alcohols (Honsho et al., 2013; Buchert et al., 2014). RCDP type 5 results from a genetic mutation leading to specific loss of only the Pex5 long isoform (Pex5L). While both the long and short Pex5 isoforms recognize PTS1-containing proteins, Pex5L is a co-receptor with Pex7 for the import of PTS2-containing proteins, and its loss results only in impaired PTS2-tagged protein import and RCDP phenotype (Barøy et al., 2015).

Zellweger spectrum disorders

Peroxisomal biogenesis disorders in the Zellweger spectrum are a heterogeneous group of genetic disorders encompassing Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. They are caused by a mutation in one of the dozen Pex genes required for normal assembly and functions of peroxisomes and affect approximately 1 in 50,000 individuals. Mutations in Pex1 are the most common, accounting for nearly 70% of cases. However, mutations in Pex3, Pex16, and Pex19 result in the complete absence of peroxisomes and are coupled to the most severe phenotypes (Steinberg et al., 2012). Like RCDP, Zellweger spectrum disorders (ZSD) present with a broad range of clinical characteristics, which include craniofacial abnormalities, chondrodysplasia punctata, hepatomegaly, kidney abnormalities, and vision problems. Infants with a severe form of ZSD (Zellweger syndrome) have multiple developmental abnormalities and generally die within the first year of life. Along with blood accumulation of very long chain and branched chain fatty acids, which require peroxisomes for their oxidation, decreased ether lipid levels in red blood cell membranes are one of the criteria for diagnosis of ZSD (Braverman et al., 2016).

Generation of mouse models of ether lipid deficiency has shed some light on the pathophysiology of peroxisomal biogenesis disorders. These mice show defects in neuronal development and myelination (Brites, 2003; Rodemer et al., 2003; Teigler et al., 2009). As discussed above, Schwann cells of ether-lipid deficient mice show impaired differentiation and myelination resulting from decreased Akt signaling, presumably due to the necessity of plasmalogens for correct recruitment of Akt to the membrane (da Silva et al., 2014).

Alterations in ether lipid levels in common disease states

Neurological disorders

Alzheimer’s disease (AD) pathology is associated with decreased ether lipids, particularly plasmalogens, in the brain (Ginsberg et al., 1995, 1998; Han et al., 2001; Han, 2005). Additionally, serum levels of ethanolamine plasmalogens in AD patients are decreased and correlate with the severity of disease progression (Goodenowe et al., 2007; Wood et al., 2010). Given this relationship, serum plasmalogen levels have even been used to successfully stratify diseased patients (Wood et al., 2016). Increased β-amyloid (Aβ) levels associated with AD have been shown to promote oxidative stress in the brain, leading to loss of peroxisomal function. This in turn decreases AGPS (the rate-limiting enzyme of ether lipid synthesis) activity, ultimately lowering plasmalogen levels (Grimm et al., 2011). In addition, certain ethanolamine plasmalogen species are thought to have the ability to destabilize existing Aβ fibrils in vitro and prevent the formation of new fibrils in a dose dependent manner, providing another mechanism by which plasmalogen loss facilitates AD pathology (Yamashita et al., 2015b).

Abnormal ether lipid levels have also been implicated in other neurological disorders. Red blood cells and fibroblasts collected from schizophrenia patients were recently shown to be significantly decreased in plasmalogen levels (Tessier et al., 2016; Huang et al., 2016). In addition, patients with Parkinson’s disease show severe alterations in neuronal membrane composition, including a significant decrease in postmortem frontal cortex lipid raft plasmalogens levels (Fabelo et al., 2011). Additional work is needed to understand the molecular mechanism through which reduced ether lipids contribute to these pathologies.

Cancer

Decades ago it was observed that cancer cells have remarkably higher levels of ether lipids compared to normal cells, suggesting that ether lipids may be involved in cancer pathogenesis (Snyder et al., 1966, 1969; Snyder and Wood, 1969; Albert and Anderson, 1977; Roos and Choppin, 1984). Indeed, increased ether lipids are correlated with more aggressive cancers, and knockdown of AGPS in a variety of cancer cell lines results in impaired pathogenicity (Benjamin et al., 2013). A small molecule screen identified an inhibitor of AGPS that decreases ether lipid levels and appears to reduce pathogenicity of human cancer cells in vitro (Piano et al., 2015). Recently, a lipidomics study on breast cancer patients identified increased plasma ether-linked phosphatidylcholine species as a diagnostic marker for breast cancer (Chen et al., 2016). It is unclear whether ether lipids play a structural or signaling role in promoting cancer progression.

Metabolic disorders

Levels of plasmalogen and other ether-linked phosphatidylcholine species are increased in steatotic livers of high fat diet-fed mice, although it is unclear whether this is due to increased synthesis, reduced degradation, or impaired hepatic release (Eisinger et al., 2014). One possibility is that increased plasmalogens may be an indication of increased activity of protective mechanisms against oxidative stress (Barr et al., 2012). However, serum plasmalogen levels are decreased in patients with nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) as compared to healthy controls (Puri et al., 2009). This drop in plasmalogen levels is more severe in NASH patients as opposed to simple steatosis patients suggesting the possibility to use serum lipidomics as a biomarker to diagnose and stratify the disease. Recent studies suggest a protective role of plasmalogens against NASH. Free cholesterol-induced NASH in mice was associated with decreased levels of docosahexaenoic acid-containing plasmalogens and impaired expression of PPARα, a critical transcriptional regulator of fatty acid oxidation. Rescue of plasmalogen levels by alkyl glycerol treatment prevented hepatic steatosis and NASH through PPARα-dependent increase in fatty acid oxidation, suggesting a role for endogenous plasmalogen production in PPARα signaling (Jang et al., 2017).

Decreased serum ether lipid levels have been implicated in hypertension and obesity (Pietiläinen et al., 2007; Graessler et al., 2009). In a weight-discordant twin study, obese patients showed a decrease in serum plasmalogens compared to healthy twin controls, indicating that the effect is independent of genetic makeup (Pietiläinen et al., 2007). Similarly, a follow up study by the same group showed that plasmalogens containing arachidonic acid at the sn-2 position are reduced in the adipocyte membranes of morbidly obese twins compared to metabolically healthy twins (Pietiläinen et al., 2011). Conversely, serum plasmalogen levels increase in men with aerobic training and in patients with a healthy dietary intervention (Lankinen et al., 2016; Felder et al., 2017).

Altered ether lipid levels are also associated with type 1 diabetes (T1D). Interestingly, decreased ether lipids were detected in the serum of children that were later diagnosed with T1D. The presence of these metabolic changes prior to the detection of autoantibodies suggests that ether lipid metabolism is dysregulated before the disease emerges (Orešič et al., 2008). It is unresolved whether the decreased ether lipid levels contribute to accelerating pathology of diabetes or are related to secondary metabolic changes. However, β cells are known to possess inherently poor antioxidant capacity (Lenzen et al., 1996), and this coupled with the lower levels of plasmalogens may result in enhanced susceptibility of β cells to metabolic stress and ROS contributing to the autoimmune response. Regardless of the mechanism, changes in lipid metabolism may serve as useful markers for early diagnosis.

CONCLUDING REMARKS AND FUTURE DIRECTIONS

With the rising interest in lipidomics, ether lipids have emerged as potential biomarkers of several diseases, including neurodegenerative diseases, cancer, and metabolic disorders (Eisinger et al., 2014; Chen et al., 2016; Tessier et al., 2016; Alshehry et al., 2016). However, with this observation comes the principal question: Are the changes in ether lipid levels merely a byproduct of the disease process or a contributor to disease pathogenesis? Severe phenotypes resulting from genetic loss of ether lipid production suggest that these peroxisome-derived phospholipids are responsible for fundamental cellular functions that cannot be carried out by conventional phospholipids. Decreased ether lipid synthesis is linked to multiple neurological and metabolic abnormalities, while increased levels are associated with cancer, suggesting that proper regulation of ether lipid production is required for normal physiology. Future research will be necessary to determine if targeted inhibition of the ether lipid synthetic pathway could treat malignancies. Conversely, there is a need to develop novel dietary interventions to correct pathologies associated with ether lipid deficiency. Several groups have attempted to deliver alkylglycerols in diet to boost ether lipid levels in deficient animals with variable results. While the effects of ether lipid replacement appear to be promising in peripheral tissues, the results have been less successful in correcting neurological deficits (Brites et al., 2011; Rasmiena et al., 2015; Jang et al., 2017). It will be of great interest to develop more effective synthetic ether lipid precursors that could cross the blood-brain barrier and alter the clinical course of neurological diseases.

Currently there is a wide knowledge gap in our understanding of the molecular mechanisms underlying the pathologies associated with altered production of these lipids. Much work has been done using mouse models of global ether lipid deficiency, revealing gross abnormalities associated with such manipulations (da Silva et al., 2012). Going forward it will be important to take a more fine-tuned approach through targeted inactivation of ether lipid production to better define the biological roles of these unique phospholipids, perhaps uncovering novel strategies for disease intervention.

Notes

ACKNOWLEDGEMENTS

This work was supported by NIH grant R00 DK094874.

ABBREVIATIONS

Aβ, β-amyloid; ACBD5, acyl-CoA-binding domain 5; ACS, acyl-CoA synthetase; AD, Alzheimer’s disease; AGP, 1-O-alkyl glycerol-3-phosphate; AGPS, alkylglycerone phosphate synthase; DHAP, acyl-dihydroxyacetone; EMS, ethyl methanesulfonate; FAS, fatty acid synthase; G3P, glycerol-3-phosphate; GNPAT, glyceronephosphate O-acyltransferase; GPAT, G3P acyltransferase; GSK3β, glycogen synthase kinase 3β; LPA, lysophosphatidic acid; LRM, lipid raft microdomains; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PPARγ, peroxisome proliferator-activated receptor gamma; PTS, peroxisomal targeting sequence; RCDP, Rhizomelic chondrodysplasia punctate; ROS, reactive oxygen species; T1D, type 1 diabetes; ZSD, Zellweger spectrum disorders.

COMPLIANCE WITH ETHICS GUIDELINES

John Dean and Irfan Lodhi declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by the authors.

REFERENCES

  1. Albert DH, Anderson CE (1977) Ether-linked glycerolipids in human brain tumors. Lipids 12:188–192CrossRefPubMedGoogle Scholar
  2. Albert CJ, Thukkan AK, Heuertz RM et al (2003) Eosinophil peroxidase-derived reactive brominating species target the vinyl ether bond of plasmalogens generating a novel chemoattractant, alpha -bromo fatty aldehyde. J Biol Chem 278:8942–8950. doi: 10.1074/jbc.M211634200 CrossRefPubMedGoogle Scholar
  3. Alshehry ZH, Mundra PA, Barlow CK et al (2016) Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus clinical perspective. Circulation 134:1637–1650. doi: 10.1161/CIRCULATIONAHA.116.023233 CrossRefPubMedGoogle Scholar
  4. Barøy T, Koster J, Strømme P et al (2015) A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Hum Mol Genet 24:5845–5854. doi: 10.1093/hmg/ddv305 CrossRefPubMedGoogle Scholar
  5. Barr J, Caballería J, Martínez-Arranz I et al (2012) Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 11:2521–2532. doi: 10.1021/pr201223p CrossRefPubMedPubMedCentralGoogle Scholar
  6. Benjamin DI, Cozzo A, Ji X et al (2013) Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci 110:14912–14917. doi: 10.1073/pnas.1310894110 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bräutigam C, Engelmann B, Reiss D et al (1996) Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis 119:77–88CrossRefPubMedGoogle Scholar
  8. Braverman NE, Moser AB (2012) Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta BBA Mol Basis Dis 1822:1442–1452. doi: 10.1016/j.bbadis.2012.05.008 CrossRefGoogle Scholar
  9. Braverman N, Steel G, Obie C et al (1997) Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet 15:369–376CrossRefPubMedGoogle Scholar
  10. Braverman NE, Raymond GV, Rizzo WB et al (2016) Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab 117:313–321. doi: 10.1016/j.ymgme.2015.12.009 CrossRefPubMedGoogle Scholar
  11. Brites P (2003) Impaired neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata. Hum Mol Genet 12:2255–2267. doi: 10.1093/hmg/ddg236 CrossRefPubMedGoogle Scholar
  12. Brites P, Ferreira AS, Ferreira da Silva T et al (2011) Alkyl-glycerol rescues plasmalogen levels and pathology of ether-phospholipid deficient mice. PLoS ONE 6:e28539. doi: 10.1371/journal.pone.0028539 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Brodde A, Teigler A, Brugger B et al (2012) Impaired neurotransmission in ether lipid-deficient nerve terminals. Hum Mol Genet 21:2713–2724. doi: 10.1093/hmg/dds097 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Broniec A, Klosinski R, Pawlak A et al (2011) Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic Biol Med 50:892–898. doi: 10.1016/j.freeradbiomed.2011.01.002 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Broniec A, Żądło A, Pawlak A et al (2017) Interaction of plasmenylcholine with free radicals in selected model systems. Free Radic Biol Med 106:368–378CrossRefPubMedGoogle Scholar
  16. Buchert R, Tawamie H, Smith C et al (2014) A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am J Hum Genet 95:602–610. doi: 10.1016/j.ajhg.2014.10.003 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Cader MZ, Boroviak K, Zhang Q et al (2016) C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol 17:1046–1056. doi: 10.1038/ni.3532 CrossRefPubMedGoogle Scholar
  18. Chen X, Chen H, Dai M et al (2016) Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget 7:36622–36631PubMedPubMedCentralGoogle Scholar
  19. da Silva TF, Sousa VF, Malheiro AR, Brites P (2012) The importance of ether-phospholipids: a view from the perspective of mouse models. Biochim Biophys Acta BBA Mol Basis Dis 1822:1501–1508. doi: 10.1016/j.bbadis.2012.05.014 CrossRefGoogle Scholar
  20. da Silva TF, Eira J, Lopes AT et al (2014) Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination. J Clin Investig 124:2560–2570. doi: 10.1172/JCI72063 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Davies SS, Pontsler AV, Marathe GK et al (2001) Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor ligands and agonists. J Biol Chem 276:16015–16023. doi: 10.1074/jbc.M100878200 CrossRefPubMedGoogle Scholar
  22. Eisinger K, Krautbauer S, Hebel T et al (2014) Lipidomic analysis of the liver from high-fat diet induced obese mice identifies changes in multiple lipid classes. Exp Mol Pathol 97:37–43. doi: 10.1016/j.yexmp.2014.05.002 CrossRefPubMedGoogle Scholar
  23. Fabelo N, Martín V, Santpere G et al (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17:1107CrossRefPubMedPubMedCentralGoogle Scholar
  24. Facciotti F, Ramanjaneyulu GS, Lepore M et al (2012) Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat Immunol 13:474–480. doi: 10.1038/ni.2245 CrossRefPubMedGoogle Scholar
  25. Farooqui AA, Horrocks LA (2001) Book review: plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7:232–245CrossRefPubMedGoogle Scholar
  26. Felder TK, Ring-Dimitriou S, Auer S et al (2017) Specific circulating phospholipids, acylcarnitines, amino acids and biogenic amines are aerobic exercise markers. J Sci Med Sport. doi: 10.1016/j.jsams.2016.11.011 PubMedGoogle Scholar
  27. Fu S, Yang L, Li P et al (2011) Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473:528–531. doi: 10.1038/nature09968 CrossRefPubMedPubMedCentralGoogle Scholar
  28. Gibellini F, Smith TK (2010) The Kennedy pathway—de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 62:414–428CrossRefPubMedGoogle Scholar
  29. Ginsberg L, Rafique S, Xuereb JH et al (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res 698:223–226CrossRefPubMedGoogle Scholar
  30. Ginsberg L, Xuereb JH, Gershfeld NL (1998) Membrane instability, plasmalogen content, and Alzheimer’s disease. J Neurochem 70:2533–2538CrossRefPubMedGoogle Scholar
  31. Glaser PE, Gross RW (1994) Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry (Mosc) 33:5805–5812CrossRefGoogle Scholar
  32. Goodenowe DB, Cook LL, Liu J et al (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 48:2485–2498. doi: 10.1194/jlr.P700023-JLR200 CrossRefPubMedGoogle Scholar
  33. Graessler J, Schwudke D, Schwarz PEH et al (2009) Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS ONE 4:e6261. doi: 10.1371/journal.pone.0006261 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Grimm MOW, Kuchenbecker J, Rothhaar TL et al (2011) Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease: dysregulation of plasmalogen synthesis in AD. J Neurochem 116:916–925. doi: 10.1111/j.1471-4159.2010.07070.x CrossRefPubMedGoogle Scholar
  35. Hajra AK, Das AK (1996) Lipid biosynthesis in peroxisomesa. Ann NY Acad Sci 804:129–141CrossRefPubMedGoogle Scholar
  36. Han X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2:65–77CrossRefPubMedGoogle Scholar
  37. Han XL, Gross RW (1990) Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs. Biochemistry (Mosc) 29:4992–4996CrossRefGoogle Scholar
  38. Han X, Holtzman DM, McKeel DW (2001) Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77:1168–1180CrossRefPubMedGoogle Scholar
  39. Hillebrand M, Gersting SW, Lotz-Havla AS et al (2012) Identification of a new fatty acid synthesis-transport machinery at the peroxisomal membrane. J Biol Chem 287:210–221. doi: 10.1074/jbc.M111.272732 CrossRefPubMedGoogle Scholar
  40. Hofer DC, Pessentheiner AR, Pelzmann HJ et al (2017) Critical role of the peroxisomal protein PEX16 in white adipocyte development and lipid homeostasis. Biochim Biophys Acta BBA Mol Cell Biol Lipids 1862:358–368. doi: 10.1016/j.bbalip.2016.12.009 CrossRefGoogle Scholar
  41. Honsho M, Asaoku S, Fukumoto K, Fujiki Y (2013) Topogenesis and homeostasis of fatty acyl-CoA reductase 1. J Biol Chem 288:34588–34598. doi: 10.1074/jbc.M113.498345 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Hossain MS, Ifuku M, Take S et al (2013) Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PLoS ONE 8:e83508. doi: 10.1371/journal.pone.0083508 CrossRefPubMedPubMedCentralGoogle Scholar
  43. Hossain MS, Mineno K, Katafuchi T (2016) Neuronal orphan G-Protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling. PLOS ONE 11:e0150846. doi: 10.1371/journal.pone.0150846 CrossRefPubMedPubMedCentralGoogle Scholar
  44. Hua R, Cheng D, Coyaud É et al (2017) VAPs and ACBD5 tether peroxisomes to the ER for peroxisome maintenance and lipid homeostasis. J Cell Biol. doi:  10.1083/jcb.201608128
  45. Huang JH, Park H, Iaconelli J et al (2016) Unbiased metabolite profiling of schizophrenia fibroblasts under stressful perturbations reveals dysregulation of plasmalogens and phosphatidylcholines. J Proteome Res. doi: 10.1021/acs.jproteome.6b00628 Google Scholar
  46. James PF, Lake AC, Hajra AK et al (1997) An animal cell mutant with a deficiency in acyl/alkyl-dihydroxyacetone-phosphate reductase activity: effects on the biosynthesis of ether-linked and diacyl glycerolipids. J Biol Chem 272:23540–23546CrossRefPubMedGoogle Scholar
  47. Jang JE, Park H-S, Yoo HJ et al (2017) Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis. Hepatology. doi: 10.1002/hep.29039 PubMedCentralGoogle Scholar
  48. Khaselev N, Murphy RC (1999) Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic Biol Med 26:275–284CrossRefPubMedGoogle Scholar
  49. Komljenovic D, Sandhoff R, Teigler A et al (2009) Disruption of blood-testis barrier dynamics in ether-lipid-deficient mice. Cell Tissue Res 337:281–299. doi: 10.1007/s00441-009-0809-7 CrossRefPubMedGoogle Scholar
  50. LaBelle EF, Hajra AK (1974) Purification and kinetic properties of acyl and alkyl dihydroxyacetone phosphate oxidoreductase. J Biol Chem 249:6936–6944PubMedGoogle Scholar
  51. Lankinen M, Schwab U, Kolehmainen M et al (2016) A healthy nordic diet alters the plasma lipidomic profile in adults with features of metabolic syndrome in a multicenter randomized dietary intervention. J Nutr 146:662–672. doi: 10.3945/jn.115.220459 CrossRefGoogle Scholar
  52. Lenzen S, Drinkgern J, Tiedge M (1996) Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463–466CrossRefPubMedGoogle Scholar
  53. Li Z, Agellon LB, Allen TM et al (2006) The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 3:321–331. doi: 10.1016/j.cmet.2006.03.007 CrossRefPubMedGoogle Scholar
  54. Lodhi IJ, Yin L, Jensen-Urstad APL et al (2012) Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesity. Cell Metab 16:189–201. doi: 10.1016/j.cmet.2012.06.013 CrossRefPubMedPubMedCentralGoogle Scholar
  55. Lodhi IJ, Wei X, Yin L et al (2015) Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. Cell Metab 21:51–64. doi: 10.1016/j.cmet.2014.12.002 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Lohner K (1996) Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Chem Phys Lipids 81:167–184CrossRefPubMedGoogle Scholar
  57. Luoma AM, Kuo F, Cakici O et al (2015) Plasmalogen phospholipids protect internodal myelin from oxidative damage. Free Radic Biol Med 84:296–310. doi: 10.1016/j.freeradbiomed.2015.03.012 CrossRefPubMedGoogle Scholar
  58. Maeba R, Sawada Y, Shimasaki H et al (2002) Ethanolamine plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free radicals. Chem Phys Lipids 120:145–151CrossRefPubMedGoogle Scholar
  59. Marrink S-J, Mark AE (2004) Molecular view of hexagonal phase formation in phospholipid membranes. Biophys J 87:3894–3900. doi: 10.1529/biophysj.104.048710 CrossRefPubMedPubMedCentralGoogle Scholar
  60. McIntyre TM, Pontsler AV, Silva AR et al (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc Natl Acad Sci 100:131–136CrossRefPubMedGoogle Scholar
  61. Morand OH, Zoeller RA, Raetz CR (1988) Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation. J Biol Chem 263:11597–11606PubMedGoogle Scholar
  62. Motley AM, Hettema EH, Hogenhout EM et al (1997) Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. Nat Genet 15:377–380CrossRefPubMedGoogle Scholar
  63. Mueller HW, O’Flaherty JT, Wykle RL (1982) Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. Lipids 17:72–77CrossRefPubMedGoogle Scholar
  64. Mueller HW, O’Flaherty JT, Greene DG et al (1984) 1-O-alkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. J Lipid Res 25:383–388PubMedGoogle Scholar
  65. Munn NJ (2003) Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 44:182–192. doi: 10.1194/jlr.M200363-JLR200 CrossRefPubMedGoogle Scholar
  66. Nagan N, Zoeller RA (2001) Plasmalogens: biosynthesis and functions. Prog Lipid Res 40:199–299CrossRefPubMedGoogle Scholar
  67. Orešič M, Simell S, Sysi-Aho M et al (2008) Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205:2975–2984. doi: 10.1084/jem.20081800 CrossRefPubMedPubMedCentralGoogle Scholar
  68. Paltauf F (1994) Ether lipids in biomembranes. Chem Phys Lipids 74:101–139CrossRefPubMedGoogle Scholar
  69. Piano V, Benjamin DI, Valente S et al (2015) Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents. ACS Chem Biol 10:2589–2597. doi: 10.1021/acschembio.5b00466 CrossRefPubMedPubMedCentralGoogle Scholar
  70. Pietiläinen KH, Sysi-Aho M, Rissanen A et al (2007) Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects—a monozygotic twin study. PLoS ONE 2:e218. doi: 10.1371/journal.pone.0000218 CrossRefPubMedPubMedCentralGoogle Scholar
  71. Pietiläinen KH, Róg T, Seppänen-Laakso T et al (2011) Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biol 9:e1000623. doi: 10.1371/journal.pbio.1000623 CrossRefPubMedPubMedCentralGoogle Scholar
  72. Pike LJ, Han X, Chung K-N, Gross RW (2002) Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of Caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry (Mosc) 41:2075–2088. doi: 10.1021/bi0156557 CrossRefGoogle Scholar
  73. Purdue PE (1997) Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTSZ. Nat Genet 15:381CrossRefPubMedGoogle Scholar
  74. Puri P, Wiest MM, Cheung O et al (2009) The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50:1827–1838CrossRefPubMedPubMedCentralGoogle Scholar
  75. Rasmiena AA, Barlow CK, Stefanovic N et al (2015) Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice. Atherosclerosis 243:598–608. doi: 10.1016/j.atherosclerosis.2015.10.096 CrossRefPubMedGoogle Scholar
  76. Reiss D, Beyer K, Engelmann B (1997) Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J 323:807–814CrossRefPubMedPubMedCentralGoogle Scholar
  77. Rodemer C, Thai T-P, Brugger B et al (2003) Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum Mol Genet 12:1881–1895. doi: 10.1093/hmg/ddg191 CrossRefPubMedGoogle Scholar
  78. RooS DS, Choppin PW (1984) Tumorigenicity of cell lines with altered lipid composition. Proc Natl Acad Sci 81:7622–7626CrossRefPubMedPubMedCentralGoogle Scholar
  79. Skaff O, Pattison DI, Davies MJ (2008) The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase-derived oxidants: a kinetic study . Biochemistry (Mosc) 47:8237–8245. doi: 10.1021/bi800786q CrossRefGoogle Scholar
  80. Snyder F (1999) The ether lipid trail: a historical perspective. Biochim Biophys Acta BBA Mol Cell Biol Lipids 1436:265–278CrossRefGoogle Scholar
  81. Snyder F, Wood R (1969) Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues. Cancer Res 29:251–257PubMedGoogle Scholar
  82. Snyder F, Cress EA, Stephens N (1966) An unidentified lipid prevalent in tumors. Lipids 1:381–386CrossRefPubMedGoogle Scholar
  83. Snyder F, Blank ML, Morris HP (1969) Occurrence and nature of O-alkyl and O-alk-1-enyl moieties of glycerol in lipids of Morris transplanted hepatomas and normal rat liver. Biochim Biophys Acta BBA Lipids Lipid Metab 176:502–510CrossRefGoogle Scholar
  84. Steinberg SJ, Raymond GV, Braverman NE, Moser AB (2012) Peroxisome biogenesis disorders, Zellweger syndrome spectrum.Google Scholar
  85. Teigler A, Komljenovic D, Draguhn A et al (2009) Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum. Hum Mol Genet 18:1897–1908. doi: 10.1093/hmg/ddp110 CrossRefPubMedPubMedCentralGoogle Scholar
  86. Tessier C, Sweers K, Frajerman A et al (2016) Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations. Transl Psychiatry 6:e906. doi: 10.1038/tp.2016.142 CrossRefPubMedPubMedCentralGoogle Scholar
  87. Thukkani AK, Hsu F-F, Crowley JR et al (2002) Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: Production Of The Chemoattractant, 2-Chlorohexadecanal. J Biol Chem 277:3842–3849. doi: 10.1074/jbc.M109489200 CrossRefPubMedGoogle Scholar
  88. Tsukahara T, Tsukahara R, Yasuda S et al (2006) Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor. J Biol Chem 281:3398–3407. doi: 10.1074/jbc.M510843200 CrossRefPubMedGoogle Scholar
  89. Tulodziecka K, Diaz-Rohrer BB, Farley MM et al (2016) Remodeling of the postsynaptic plasma membrane during neural development. Mol Biol Cell 27:3480–3489CrossRefPubMedPubMedCentralGoogle Scholar
  90. Volmer R, van der Ploeg K, Ron D (2013) Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci 110:4628–4633. doi: 10.1073/pnas.1217611110 CrossRefPubMedPubMedCentralGoogle Scholar
  91. Wang G, Wang T (2010) The role of plasmalogen in the oxidative stability of neutral lipids and phospholipids. J Agric Food Chem 58:2554–2561. doi: 10.1021/jf903906e CrossRefPubMedGoogle Scholar
  92. White AL, Modaff P, Holland-Morris F, Pauli RM (2003) Natural history of rhizomelic chondrodysplasia punctata. Am J Med Genet 118A:332–342. doi: 10.1002/ajmg.a.20009 CrossRefPubMedGoogle Scholar
  93. Wood P, mankidy R, Ritchie S et al (2010) Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35:59–62. doi: 10.1503/jpn.090059 CrossRefPubMedPubMedCentralGoogle Scholar
  94. Wood PL, Locke VA, Herling P et al (2016) Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer’s disease (LOAD). BBA Clin 5:25–28. doi: 10.1016/j.bbacli.2015.11.004 CrossRefPubMedGoogle Scholar
  95. Yamashita S, Kanno S, Nakagawa K et al (2015a) Extrinsic plasmalogens suppress neuronal apoptosis in mouse neuroblastoma Neuro-2A cells: importance of plasmalogen molecular species. RSC Adv 5:61012–61020. doi: 10.1039/C5RA00632E CrossRefGoogle Scholar
  96. Yamashita S, Kiko T, Fujiwara H et al (2015b) Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer’s disease: possible interactions between amyloid-β and these lipids. J Alzheimers Dis 50:527–537. doi: 10.3233/JAD-150640 CrossRefGoogle Scholar
  97. Yen C-LE, Mar M, Zeisel SH (1999) Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase. FASEB J 13:135–142CrossRefPubMedGoogle Scholar
  98. Zhang C, Baker DL, Yasuda S et al (2004) Lysophosphatidic acid induces neointima formation through PPARγ activation. J Exp Med 199:763–774. doi: 10.1084/jem.20031619 CrossRefPubMedPubMedCentralGoogle Scholar
  99. Zoeller RA, Morand OH, Raetz CR (1988) A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem 263:11590–11596PubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Endocrinology, Metabolism and Lipid Research, Department of MedicineWashington University School of MedicineSaint LouisUSA

Personalised recommendations